Press release
Sep 12, 2019

Sosei Heptares hosts Investor R&D Event highlighting innovative research and development approaches and strong pipeline momentum


Tokyo, Japan and London, UK, 12 September 2019 – Sosei Group Corporation (“the Company”; TSE: 4565) today will host an Investor R&D Event in Tokyo, Japan, discussing how the integration of its proprietary StaR® technology and approach to AI in structure-based drug discovery at its new state-of-the-art R&D center, positions the Company well to continue delivering high-quality drug candidates, strategic partnerships and strong shareholder value over the long term.

The Company is delighted to welcome Professor Yoshinori Fujiyoshi, Japan’s leading academic in the field of structural biology, as Keynote Speaker. He will present his insights to drug design based on structure analysis by cryo-electron microscopy (cryo-EM). Professor Fujiyoshi is a Distinguished Professor at Tokyo Medical and Dental University and Emeritus Professor at Kyoto University.

In addition, select Sosei Heptares scientists will showcase the following topics during the event:

  • A Day in the Life at Sosei Heptares’ UK R&D Center – Dr. Rie Suzuki, Director, Translational Sciences
  • The Power of StaR® Technology – Providing a Leadership Advantage in GPCR Drug Design – Dr. Stacey Southall, Associate Director, Head of Biophysics
  • Integrating Artificial Intelligence Approaches to Enhance GPCR Drug Discovery – Dr. Chris de Graaf, Director, Head of Computational Chemistry
  • R&D Pipeline Update – Translating Cutting-edge Science into New Drug Candidates – Dr. Malcolm Weir, EVP, Chief R&D Officer

The event will take place from 9:30-12:30 JST at the Hotel Grand Arc Hanzomon and will be video recorded. More information on the presentations and details for accessing the presentation materials and video recordings are below. No new material information will be disclosed.


A Day in the Life at Sosei Heptares’ UK R&D Center

Dr. Rie Suzuki, Director, Translational Sciences, will lead a virtual tour of the Company’s state-of-the-art UK R&D facilities in Granta Park, Cambridge where it currently employs approximately 120 scientists.

Dr. Suzuki will also discuss her involvement in the development of new therapies for gastrointestinal (GI) diseases, one of the Company’s core therapeutic areas. She will also host an interview with Dr. Simon Gabe, a leading UK gastroenterologist consulting at St Mark’s Hospital (London, UK), to talk about the devastating physical and emotional burden of GI diseases such as Short Bowel Syndrome (SBS) and Inflammatory Bowel Disease (IBD), and why Sosei Heptares is focussed on such areas of high unmet medical need.

The virtual tour and Dr. Suzuki’s interview with Dr. Gabe will be available in the CHISHIKI Science Center section of the Sosei Heptares website following the event.


The Power of StaR® Technology – Providing a Leadership Advantage in GPCR Drug Design

Dr. Stacey Southall, Associate Director, Head of Biophysics, describes what G protein-coupled receptors (GPCRs) are, why Sosei Heptares targets them and how the Company harnesses the power of its revolutionary StaR® technology to give it a unique advantage in GPCR drug design.

In-depth examples of how StaR® technology has been successfully employed will be presented, with specific references to important GPCR drug targets, including the PAR2 receptor and Adenosine A2a receptor. Application of this technology as part of a comprehensive structure-based drug design (SBDD) platform has led to, and continues to attract, a large number of strategic multi-target collaborations and partnerships with global pharmaceutical companies.

Looking into the future, Dr. Southall explains how StaR® proteins are at the heart of exploiting powerful emerging technologies such as cryo-EM.


Integrating Artificial Intelligence Approaches to Enhance GPCR Drug Discovery

Dr. Chris de Graaf, Director, Head of Computational Chemistry, delves into the exciting topic of Artificial Intelligence (AI) and machine learning in drug discovery and how Sosei Heptares will use these cutting-edge approaches to enhance its drug design capabilities and extend its competitive advantage in GPCR-focused SBDD. Despite being a relatively new area, AI has the potential to revolutionize drug discovery and development in the pharmaceutical industry and improve patient treatment over the next 10-20 years.

Sosei Heptares is actively exploring the application of Computational and AI approaches to improve GPCR drug discovery in defined areas including: StaR® construct design, ligand or drug design, pharmacology/pharmacokinetics prediction, and target and disease indication selection.


R&D Pipeline Update – Translating Cutting-edge Science into New Drug Candidates

Dr. Malcolm Weir, EVP, Chief R&D Officer, outlines the Company’s strong business momentum and how its continued investment in innovative GPCR SBDD technology will maintain Sosei Heptares’ world leadership status into the future.

Dr. Weir explores some of the specific diseases and health issues that Sosei Heptares is addressing to develop new therapies and build a better life for patients, together with an update of the Company’s most advanced programs, including partnered programs with Allergan and AstraZeneca, and in-house programs mGlu5, SSTR5, CGRP and GPR35.


Presentations and Video Recordings

The Investor R&D Event will be video recorded and accessible from the Presentations and Webcasts section of Sosei Heptares’ website. All presentations by Sosei Heptares scientists will be available immediately after the event and video recordings will be made available a few days following the event.

–        ENDS        –


 DOWNLOAD PDF